

The tuberculosis emergency in eastern Europe



Recently, when it comes to tuberculosis, there has been no shortage of bad news. WHO announced in November that, once again, the disease has earned the dubious distinction of being the leading infectious killer of adults.¹ And, now, in *The Lancet HIV*, Daria Podlekareva and colleagues² show that almost one in every three people living with HIV in eastern Europe who is diagnosed with tuberculosis is dead within a year.

Although unsettling, there is nothing surprising about the results of this study. Once again, we are presented with evidence that two familiar stumbling blocks are killing people with tuberculosis at unprecedented rates: HIV co-infection and drug-resistant forms of the disease.³ The noxious synergy⁴ between tuberculosis and HIV has been well described, with many different solutions proposed for halting this mortality. However, this paper presents clear evidence that straightforward interventions—such as drug-susceptibility testing for tuberculosis and the prompt initiation of antiretroviral therapy in all patients with tuberculosis—are still not being implemented.

Drug resistance continues to be a formidable foe, with this study documenting a death rate three-times higher in those with drug-resistant tuberculosis than in those with fully susceptible disease. In western Europe, however, no such excess mortality was recorded, probably because effective interventions are part of routine tuberculosis practice, similar to those described in a recent *Lancet* Series on eliminating the disease.⁵ Yet there has been great hesitation on the part of a tuberculosis community more comfortable with tradition than innovation to demand these interventions be implemented worldwide and urgently, even though similar outbreaks are also being reported in places as disparate as Papua New Guinea⁶ and India.⁷ Because most drug-resistant tuberculosis comes from primary transmission,⁸ treatment as prevention must become the prevailing strategy to stop the spread of drug-resistant tuberculosis, as is the case for HIV.⁹ This means rapid diagnosis of drug-resistant tuberculosis with expeditious initiation of effective therapy for everyone who presents with signs and symptoms of the disease.¹⁰ Effective therapy must include, from the beginning, the most powerful drugs available to treat drug-resistant tuberculosis. Post-exposure



Zephyrus/Science Photo Library

Lancet HIV 2016

Published Online
February 1, 2016
[http://dx.doi.org/10.1016/S2352-3018\(16\)00002-3](http://dx.doi.org/10.1016/S2352-3018(16)00002-3)

See Online/Articles
[http://dx.doi.org/10.1016/S2352-3018\(15\)00252-0](http://dx.doi.org/10.1016/S2352-3018(15)00252-0)

management of people who come into contact with drug-resistant tuberculosis must also be implemented, not as an add-on contact-tracing activity, but as an essential strategy for saving lives.¹¹ Finally, tuberculosis treatment is based on a fundamental mistrust between health-care providers and those living with the disease, including stigmatising language¹² and the patronising direct observation of pill taking—no wonder the model is failing.¹³

Recent reflections on shortcomings in the global management of deadly infectious diseases promise change to better respond when outbreaks and emergencies occur in the future.¹⁴ The data presented by Podlekareva and colleagues reveal a health emergency with severe consequences that is happening now. We must respond not just with plans and words, but with measurable action. If not, we should be prepared for more bad news in the months and years to come.

*Jennifer Furin, Petros Isaakidis

Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA (JF); and Médecins Sans Frontières, Mumbai, India (PI)
jff38@case.edu

We declare no competing interests.

- 1 WHO. Global Tuberculosis Report 2015. Geneva; World Health Organization, 2015.
- 2 Podlekareva DN, Efsen AMW, Schultze A, et al, and the TB:HIV study group in EuroCoord. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. *Lancet HIV* 2016; published online Feb 1. [http://dx.doi.org/10.1016/S2352-3018\(15\)00252-0](http://dx.doi.org/10.1016/S2352-3018(15)00252-0).
- 3 Isaakidis P, Casas ECC, Das M, et al. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and

- meta-analysis. *Int J Tuberc Lung Dis* 2015; **19**: 969–78.
- 4 Farmer P. Infections and inequalities: the modern plagues. Berkley: University of California Press, 1999.
 - 5 Keshavjee S, Dowdy D, Swaminathan S. Stopping the body count: a comprehensive approach to move towards zero tuberculosis deaths. *Lancet* 2015; published online Oct 26. [http://dx.doi.org/10.1016/S0140-6736\(15\)00319-0](http://dx.doi.org/10.1016/S0140-6736(15)00319-0).
 - 6 Hiasihri S, Aia P, John NL, et al. Primary transmission of drug-resistant tuberculosis in South Fly District, Western Province, Papua New Guinea. 46th Union World Conference on Lung Health; Cape Town, South Africa; Dec 2–6, 2015.
 - 7 Isaakidis P, Das M, Kumar AMV, et al. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India. *PLoS One* 2014; **9**: e110461.
 - 8 Shah NS, Brust J, Mathema B, et al. Majority of XDR TB cases are due to transmission in a high-HIV-prevalence setting. Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 23–26, 2015. Abstract 92.
 - 9 Sigaloff K, Lange J, Montaner J. Global response to HIV: treatment as prevention or treatment for treatment. *Clin Infect Dis* 2014; **59** (suppl 1): S7–S11.
 - 10 Lessem E, Cox H, Daniels C, et al. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives. *Int J Infect Dis* 2014; **32**: 56–60.
 - 11 Seddon JA, Fred D, Amanullah F, et al. Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations. Policy Brief No. 1. Dubai: Harvard Medical School Center for Global Health Delivery–Dubai, 2015.
 - 12 Frick M, von Delft D, Kumar B. End stigmatizing language in tuberculosis research and practice. *BMJ* 2015; **350**: h1479.
 - 13 Daftary A, Padayatchi N, O'Donnell M. Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. *Glob Public Health* 2014; **9**: 1107–16.
 - 14 Chan, M. Learning from Ebola: readiness for outbreaks and emergencies. *Bull World Health Organ* 2015; **93**: 818–18A.